Physician
Hematology
Dr. Richard M. Elledge, MD
|
|
Give Review
Richard Elledge is an expert in the field of Hematology. He attended University of Texas Medical School. He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Whos Who in Medicine and Healthcare". Richard Elledge is a published doctor as well. He has 81 publications published. The latest was: Models for early chemoprevention trials in breast cancer. He is registered with Medicare and accepts Medicare payments.
Publications
- A Phase II Trial of Capecitabine Concomitantly With Whole-Brain Radiotherapy Followed by Capecitabine and Sunitinib for Brain Metastases From Breast Cancer.
- A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast Cancer after aromatase inhibitor (AI) failure.
- Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier.
- Short communication: dental anxiety levels and outcomes of care: a preliminary report on experiences of a sedation assessment clinic.
- Molecular markers for predicting response to tamoxifen in breast Cancer patients.
- Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast Cancer progressin...
- Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast Cancer versus megestrol acetate.
- A phase I and pharmacologic study of capecitabine and paclitaxel in breast Cancer patients.
- The p53 tumor-suppressor gene in human breast Cancer.
- Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast Cancer.
- Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast Cancer.
- A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast Cancer.
- Self-blame, self-forgiveness, and spirituality in breast Cancer survivors in a public sector setting.
- Self-forgiveness, spirituality, and psychological adjustment in women with breast Cancer.
- Optimism, social support and psychosocial functioning among women with breast Cancer.
- Long-term clinical response in leptomeningeal metastases from breast Cancer treated with capecitabine monotherapy: a case report.
- Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast Cancer.
- The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
- Imaging of lymph flow in breast Cancer patients after microdose administration of a near-infrared fluorophore: feasibility study.
- Paget disease of a nipple graft following completion of a Breast reconstruction with a nipple-sharing technique.
- Primary breast Cancer phenotypes associated with propensity for central nervous system metastases.
- Medical and psychosocial predictors of delay in seeking medical consultation for Breast symptoms in women in a public sector setting.
- Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast Cancer.
- Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast Cancer in postmenopausal women previously untreated with endocrine therapy: a multinati...
- Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast Cancer patients.
- Neoadjuvant trastuzumab induces apoptosis in primary breast Cancers.
- Prognostic value of p53 for local failure in mastectomy-treated breast Cancer patients.
- Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamox...
- Tumor characteristics and clinical outcome of elderly women with breast Cancer.
- Caution concerning micrometastatic Breast carcinoma in sentinel lymph nodes.
- Tumor characteristics and clinical outcome of tubular and mucinous Breast carcinomas.
- Prognostic and predictive value of p53 and p21 in breast Cancer.
- Models for early chemoprevention trials in breast Cancer.
- p53 mutation and tamoxifen resistance in breast Cancer.
- Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic Breast canc...
- Radiation therapy and survival in breast Cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.
- bcl-2 and apoptosis in lymph node positive Breast carcinoma.
- HER-2 expression and response to tamoxifen in estrogen receptor-positive breast Cancer: a Southwest Oncology Group Study.
- Oestrogen receptors and breast Cancer.
- bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast Cancer: a Southwest Oncology Group study.
- WAF1/CIP1 protein expression in human Breast tumors.
- Assessing p53 status in breast Cancer prognosis: where should you put the thermometer if you think your p53 is sick?
- Life and death by p53.
- Prognostic factors and therapeutic decisions in axillary node-negative breast Cancer.
- William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast Cancer.
- Prognostic significance of p53 gene alterations in node-negative breast Cancer.
- The ER-positive/PgR-negative breast Cancer phenotype is not associated with mutations within the DNA binding domain.
- Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast Cancers from pregnant patients.
- Rising levels of estrogen receptor in breast Cancer over 2 decades.
- p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast Cancer.
- Evaluation of thymidylate synthase RNA expression by polymerase chain reaction.
- Tumor biologic factors and breast Cancer prognosis among white, Hispanic, and black women in the United States.
- Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast Cancer.
- The p53 tumor suppressor gene in breast Cancer.
- Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone ...
- Inhibition of estrogen receptor action by a naturally occurring variant in human Breast tumors.
- Prognostic factors in axillary node-negative breast Cancer.
- Prognostic factors in breast Cancer.
- Clinical management of women with genomic BRCA1 and BRCA2 mutations.
- Ductal lavage for detection of cellular atypia in women at high risk for breast Cancer.
- Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast Cancer.
- BRCA1 in clinical breast Cancer.
- The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast Cancer.
- Epidermal growth factor receptor expression in breast Cancer association with biologic phenotype and clinical outcomes.
- Association of surgery with improved survival in stage IV breast Cancer patients.
- The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.
- Molecular heterogeneity of inflammatory breast Cancer: a hyperproliferative phenotype.
- Tales from a targeted therapy.
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival Analysis of two multicenter trials.
- Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast Cancer.
- Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast Cancers.
- Premalignant and in situ Breast disease: biology and clinical implications.
- Estrogen receptor-positive, progesterone receptor-negative breast Cancer: association with growth factor receptor expression and tamoxifen resistance.
- HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast Cancer: a southwest oncology group study.
- Infiltrating lobular carcinoma of the Breast: tumor characteristics and clinical outcome.
- Neoadjuvant trastuzumab and docetaxel in breast Cancer: preliminary results.
- A roundtable discussion of aromatase inhibitors as therapy for breast Cancer.
- Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast Cancer da...
- Survival of patients with metastatic Breast carcinoma: importance of prognostic markers of the primary tumor.
- Adenoid cystic carcinoma of the Breast: molecular markers, treatment, and clinical outcome.
Schools
University of Texas At Houston Medical School At Houston
Meth Ctrl Hospital
University Of Tx Health Cntr
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Whos Who in Medicine and Healthcare
Education
-
University of Texas Health Science Center -
University of Texas Medical School
Hospital
-
South Texas Veterans Health Care System -
University Health System
Drug Facts
| NPI NUMBER | 1982784229 | |
| NPPES Provider LastName | ELLEDGE | |
| NPPES Provider FirstName | RICHARD | |
| NPPES Provider ZIPCode | 782294427 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 363.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 31.0 | |
| Percent Opioid Claims | 8.54 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1982784229 |
| Last Name Of The Provider | ELLEDGE |
| First Name Of The Provider | RICHARD |
| View All |
Similar Doctors
|
|
Dr. Michael B. Osswald, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gladys I. Rodriguez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anu Dham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth A. Bowhay, MD |
|
|
Dr. Sasha C. Strain, MD |